Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Artificial intelligence reads brain scans to detect hidden tumor type

NCT ID NCT07673705

Diagnosis Sponsor: Deep Learning Institute of Radiological Sciences Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time

Summary

This study tests whether an artificial intelligence system called GliomaAI-Oligo can detect a specific type of brain tumor (oligodendroglioma) from routine MRI scans. Researchers will use over 1,300 existing, anonymized scans from multiple hospitals to train and evaluate the AI. No new tests or visits are needed—the goal is to see if the AI can match the accuracy of traditional biopsy-based diagnosis.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
GliomaAI-Oligo (artificial intelligence software)
What this could lead to
If successful, this AI could help doctors diagnose oligodendroglioma faster and more accurately without invasive biopsies.
What could go wrong
The AI is still being tested on existing scans, not in real-time clinical use. It may not perform as well across all hospitals or patient groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

1,372 people

The number who actually took part.

Started

Mar 2017

Finished

Jul 2021

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with glioma diagnosis included in the TCIA cohort.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult (\>=18 years of age) * Having pre op MRI scan * Having biopsy / surgery * Having post biopsy/ surgery histology diagnosis and genetic analysis. Exclusion Criteria: * MRI scan significantly degraded by motion or other artefact * Incomplete genetic analysis * Prior treatment (e.g., radiotherapy or chemotherapy) before baseline MRI

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for 1P19Q codeletion are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

astrocytoma (excluding glioblastoma) brain cancer disease glioma oligodendroglioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

1P19Q codeletion GLIOMA Glioma (diagnosis) IDH-mutant glioma (oligodendroglioma, astrocytoma) Oligodendroglioma

Contacts and locations

Locations

  • Deep Learning Institute of Radiological Sciences

    Mumbai, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.